GLP-1 drugs like Ozempic have been a game-changer in treating obesity, but the recent supply shortages and disruptions in access to these medications are causing concern. Researchers have now explored the effects of such disruptions on weight loss using data from over 6,000 participants in the US.
In a one-year study, nearly 90% of participants had obesity or an overweight condition like type 2 diabetes, high cholesterol, or heart disease. The programme provided access to GLP-1 drugs, digital support, and health coaching, but 73% experienced disruptions in their medication supply. Despite this, the participants lost an average of 14% of their weight, which is still a significant achievement.
The results suggest that even with disruptions in access to GLP-1 drugs, clinically significant weight loss can be achieved. However, experts highlight the need for further studies to explore the impact of health coaching and lifestyle lessons on weight loss outcomes. The study also notes that some participants were taking metformin, which may have contributed to the results.
The findings provide reassuring news for users who face difficulties accessing GLP-1 drugs due to supply shortages or insurance changes. While there is still room for improvement, the study demonstrates the effectiveness of these medications in promoting weight loss even under challenging conditions.
Source: https://www.newscientist.com/article/2488192-you-dont-need-to-take-drugs-like-ozempic-consistently-to-lose-weight